 |
Articles: Marketing/Media/ROI |
Medtronic Introduces 3D Recon Service to Enhance Endovascular Treatment of Aortic Aneurysms
Medtronic, 11/20/09
Free full text
Prior Articles
Par pharmaceutical receives final approval to market generic ultram er
Par Pharmaceutical, 11/17/09 Genzyme Receives Complete Response Letter on Lumizyme Application
Genzyme, 11/17/09
Free full text
Particles Detected in Vials from Genzymes Plant Not Expected to Impact Aldurazyme or Naglazyme
BioMarin, 11/16/09
Free full text
A Decade of Controversy: Balancing Policy With Evidence in the Regulation of Prescription Drug Advertising
American Journal of Public Health, 11/16/09 Strong E-Prescribing Growth for Walgreens
HealthDataManagement, 11/13/09 Successful purchase of trait platform with extensive product pipeline
BayNews International, 11/06/09
Free full text
Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09
Free full text
Myriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
Myriad, 11/05/09
Free full text
Carestream Health Ships 10,000th Point-of-Care CR System
Imaging Economics, 11/04/09 Shire Reports Tolerability and Clinical Effects Results of DAYTRANA from Study in Adolescents with ADHD
Shire, 11/02/09 CDW to Resell Cerner Physician Apps
HealthDataManagement, 10/28/09 FDA Determines VYVANSE was Properly Granted Five-Year Market Exclusivity
Shire, 10/27/09 Genmab achieves milestone in arzerra collaboration
Genmab, 10/27/09
Free full text
Novartis receives approval in the European Union for Exforge HCT, a new 3-in-1 treatment for high blood pressure
Novartis, 10/26/09
Free full text
Angiotech Pharmaceuticals Announces Commercial Launch of the Tan EndoGlide™ Endothelium Insertion System in the United States at the American Academy of Ophthalmology Annual Meeting
Angiotech Pharmaceuticals, 10/26/09
Free full text
Cisco to buy Tandberg for US$3 billion
Canadian Healthcare Technology, 10/26/09
Free full text
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
BayNews International, 10/23/09
Free full text
Antigenics Announces a Negative Vote From the CHMP on Oncophage Marketing Application in Europe
Antigenics, 10/23/09
Free full text
FDA Leaders Stress Science and Compliance
BioPharm, 10/23/09
Free full text
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: U.S.Pharmacist, FDA Drug Alerts, Pharmiweb
more...
|
235 Available Pages
|
|
